Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

10.1093/annonc/mdy550

Saved in:
Bibliographic Details
Main Authors: Sundar, R, Huang, KK, Qamra, A, Kim, K-M, Kim, ST, Kang, WK, Tan, ALK, Lee, J, Tan, P
Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format: Article
Language:English
Published: OXFORD UNIV PRESS 2019
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
epigenetic alternate promoter
immune checkpoint inhibition
pembrolizumab
immunotherapy
gastric cancer
TUMORS
Online Access:https://scholarbank.nus.edu.sg/handle/10635/155022
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/155022

Similar Items